03:21 , Mar 11, 2016 |  BC Extra  |  Politics & Policy

French group outlines first-in-man trial precautions

A special committee created by the French National Agency for Medicines and Health Products Safety (ANSM) made initial recommendations for first-in-man trials following a death and several hospitalizations of healthy volunteers in a Phase I...
02:34 , Jan 16, 2016 |  BC Extra  |  Clinical News

One volunteer brain-dead in Bial trial

The French Health Ministry said a Phase I trial of the oral analgesic BIA 10-2474 from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) has been halted after several healthy volunteers were hospitalized with...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Warnex supply/service news

Warnex said it terminated its lease for its facilities in Laval, Quebec, and sold all of the shares of one of its non-operating subsidiaries for a nominal payment and a promissory note in the amount...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Warnex supply/service news

Warnex disclosed in its 2012 earnings that its board is undertaking a strategic review of the company's remaining assets, following the sale of the company's operating business units. Warnex said its board has "initiated discussions...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Warnex, Biotrial Research deal

Warnex completed the sale of its Bioanalytical Services division to CRO Biotrial. As a result of the deal, Warnex will transfer its listing to the NEX stock exchange from TSX Venture. Warnex said it would...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

Warnex, Biotrial Research S.A.S. deal

Warnex will sell its Bioanalytical Services division to CRO Biotrial for C$6 million ($6 million) in cash. Warnex is also eligible for an additional payment equal to the amount by which adjusted 2012 revenues from...